[18F]-29-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil ( 18F-FMAU) in prostate cancer: Initial preclinical observations

Molecular Imaging

Volumn 11, Issue 5, 2012, Pages 426-432

  Jadvar, Hossein ^a   Yap, Li Peng ^a   Park, Ryan ^a   Li, Zibo ^a   Chen, Kai ^a   Hughes, Lindsey ^a   Kouhi, Aida ^a   Conti, Peter ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTORS; ATHYMIC; BIODISTRIBUTIONS; CELLULAR PROLIFERATIONS; EMISSION TOMOGRAPHY; HUMAN PROSTATE CANCER; HUMAN PROSTATE CANCER CELLS; IMMUNOHISTOCHEMICAL STAINING; MALE MOUSE; MOUSE MODELS; PROSTATE CANCERS; PROSTATE TUMOR; TIME POINTS; TUMOR CHARACTERIZATION; TUMOR UPTAKE;

BIOLOGICAL MATERIALS; CELL PROLIFERATION; COMPUTERIZED TOMOGRAPHY; DISEASES; MAMMALS; MUSCLE; POSITRON EMISSION TOMOGRAPHY;

TUMORS;

CLEVUDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER; URACIL ARABINOSIDE;

ANIMAL; ARTICLE; CELL PROLIFERATION; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; ORCHIECTOMY; PROSTATE TUMOR; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ARABINOFURANOSYLURACIL; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORINE RADIOISOTOPES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; ORCHIECTOMY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870976337     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2012.00004     Document Type: Article

References (25)

1. Jadvar H. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2010;52:81-9, doi:10.2967/ jnumed.110.077941.
2. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008;49:2031-41, doi:10.2967/jnumed.108.050658.
3. Shields AF. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 2006;8:141-50, doi:10.1007/s11307-006-0039-2.
4. Tehrani OS, Douglas KA, Lawhom-Crews JM, et al. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging 2008;35:1480-8, doi:10.1007/ s00259-008-0738-9.
5. Fanucchi MP, Leyland-Jones R, Young CW, et al. Phase I trial of 1-(29-deoxy-29-fluoro-1-beta-D-arabinofuranosyl)-5-methyluracil (FMAU). Cancer Treat Rep 1985;69:55-9.
6. Conti PS, AlauddinMM, Fissekis JR, et al. Synthesis of 29-fluoro-5- [11C]-methyl-1-beta-D-arabinofurasyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 1995;22:783-9, doi:10.1016/0969- 8051(95)00017-R.
7. Bading JR, Shahinian AH, Bathija P, et al. Pharmacokinetics of the thymidine analog 29-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU in rat prostate tumor cell. Nucl Med Biol 2000;27:361-8, doi:10.1016/S0969-8051(00)00100-1.
8. Wang H, Oliver P, Nan L, et al. Radiolabeled 29-fluorodeoxyuracilbeat- D-arabinofuranoside (FAU) and 29-fluoro-5-methyldeoxyuracil- beta-D-arabinofuranoside (FMAU) as tumor imaging agents in mice. Cancer Chemother Pharmacol 2002;49:419-24, doi:10.1007/s00280-002-0433-7.
9. Lu L, Samuelsson L, Bergstrom M, et al. Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers. J Nucl Med 2002;43:1688-98.
10. Mangner TJ, Klecker RW, Anderson L, et al. Synthesis of 29-deoxy- 29-[18F]fluoro-beta-D-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F] labeled FAU, FMAU, FBAU, FIAU. Nucl Med Biol 2003;30:215-24, doi:10.1016/ S0969-8051(02)00445-6.
11. de Vries EF, van Waarde A, Harmsen MC, et al. [(11)C]FMAU and [(18)F]FHPG as PET tracers for herpes simplex virus thymidine kinase activity and human cytomegalovirus infections. Nucl Med Biol 2000;27:113-9, doi:10.1016/S0969-8051 (99)00105-5.
12. Alauddin MM, Shahinian A, Gordon EM, et al. Evaluation of 29-deoxy-29-fluoro-5-methyl-1-beta-D-arabinofurasyluracil as a potential gene imaging agent for HSV-tk expression in vivo. Mol Imaging 2002;1:74-81, doi:10.1162/153535002320162723.
13. Alauddin MM, Shahinian A, Gordon EM, et al. Direct comparison of radiolabeled probes FMAU, FHBG, and FHPG as PET imaging agents for HSV1-tk expression in a human breast cancer model. Mol Imaging 2004;3:76-84, doi:10.1162/1535350041464900.
14. Kang KW, Min JJ, Chen X, et al. Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type I thymidine kinase in cell culture. Mol Imaging Biol 2005;7:296- 303, doi:10.1007/s11307-005-0010-7.
15. Sun H, Mangner TJ, Collins JM, et al. Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med 2005;46:292-6.
16. Li Z, Cai H, Conti PS. Automated synthesis of 29-deoxy-29- [18F]fluoro-5-methyl-1-b-D-arabinofuranosyluracil ([18F]-FMAU) using a one reactor radiosynthesis module. Nucl Med Biol 2011;38: 201-6, doi:10.1016/j.nucmedbio.2010.08.010.
17. Price DT, Coleman RE, Liao R, et al. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273-80, doi:10.1016/S0022-5347(05)64906-3.
18. Patel A, Jones J, Rabets J, et al. Parasagittal biopsies add minimal information in repeat saturation prostate biopsy. Urology 2004;63: 87-9, doi:10.1016/j.urology.2003.08.040.
19. Stav K, Liebovici D, Sandbank J, et al. Saturation prostate biopsy in high risk patients after multiple previous negative biopsies. Urology 2008;71:399403, doi:10.1016/j.urology.2007.11.007.
20. Bading JR, Shields A. Imaging of cell proliferation: status and prospects. J Nucl Med 2008;49:64S-80S, doi:10.2967/jnumed. 107.046391.
21. Oyama N, Hasegawa Y, Kiyono Y. Early response assessment in prostate carcinoma by 18F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumor models. Eur J Nucl Med Mol Imaging 2011;38:81-9, doi:10.1007/s00259-010-1613-z.
22. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91:1869-76, doi:10.1093/jnci/91.21.1869.
23. Kim D, Gregory CW, French FS, et al. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in CWR22 prostate xenograft. Am J Pathol 2002;160:219-26, doi:10.1016/S0002-9440(10)64365-9.
24. Doeg KA, Polomski LL, Doeg LH. Androgen control of mitochondrial and nuclear DNA synthesis in male sex accessory tissue of castrate rats. Endocrinology 1972;90:1633-8, doi:10.1210/ endo-90-6-1633.
25. Pienta KJ, Abate-Shen C, Agus DB, et al. The current state of preclinical prostate cancer animal models. Prostate 2008;68:629- 39, doi:10.1002/pros. 20726.